NCT00547261View on ClinicalTrials.gov

Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Neoplasms
Interventions
DRUG

SSR97225

every 3 weeks

Trial Locations (1)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00547261 - Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer | Biotech Hunter | Biotech Hunter